All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2020-02-11T16:59:30.000Z

What effect does idasanutlin have on TP53-mutated clones in patients with polycythemia vera?

Feb 11, 2020
Share:

Bookmark this article

The MPN Hub were pleased to speak to Jean-Jacques Kiladjian, University of Paris, Paris, FR, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. We asked: What effect does idasanutlin have on TP53-mutated clones in patients with polycythemia vera?

Jean-Jacques Kiladjian discusses the MDM2 inhibitor, idasanutlin, which can potentially reactivate the TP53 pathway in patients who don't have TP53 mutation. He talks about an observation in a study that saw idasanutlin treatment to result in the expansion of TP53-mutated clones, and when idasanutlin treatment was halted, these clones spontaneously diminished. Jean-Jacques Kiladjian explains, therefore, a careful selection of patients that are offered MDM2 inhibitors are needed.

What effect does idasanutlin have on TP53-mutated clones in patients with polycythemia vera?

Your opinion matters

HCPs, what is your preferred format for educational content on the MPN Hub?
20 votes - 78 days left ...

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox